- Home
- FCT vs CRBP Comparison
FCT vs CRBP Comparison
Compare FCT & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCT
- CRBP
- Stock Information
- Founded
- FCT 2004
- CRBP 2009
- Country
- FCT United States
- CRBP United States
- Employees
- FCT N/A
- CRBP N/A
- Industry
- FCT Finance Companies
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- FCT Finance
- CRBP Health Care
- Exchange
- FCT Nasdaq
- CRBP Nasdaq
- Market Cap
- FCT 268.9M
- CRBP 227.3M
- IPO Year
- FCT N/A
- CRBP N/A
- Fundamental
- Price
- FCT $10.34
- CRBP $18.47
- Analyst Decision
- FCT
- CRBP Strong Buy
- Analyst Count
- FCT 0
- CRBP 7
- Target Price
- FCT N/A
- CRBP $65.86
- AVG Volume (30 Days)
- FCT 106.8K
- CRBP 376.5K
- Earning Date
- FCT 01-01-0001
- CRBP 11-19-2024
- Dividend Yield
- FCT 11.29%
- CRBP N/A
- EPS Growth
- FCT N/A
- CRBP N/A
- EPS
- FCT N/A
- CRBP N/A
- Revenue
- FCT N/A
- CRBP N/A
- Revenue This Year
- FCT N/A
- CRBP N/A
- Revenue Next Year
- FCT N/A
- CRBP N/A
- P/E Ratio
- FCT N/A
- CRBP N/A
- Revenue Growth
- FCT N/A
- CRBP N/A
- 52 Week Low
- FCT $9.45
- CRBP $3.03
- 52 Week High
- FCT $10.42
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- FCT 49.33
- CRBP 40.98
- Support Level
- FCT $10.16
- CRBP $18.18
- Resistance Level
- FCT $10.34
- CRBP $20.77
- Average True Range (ATR)
- FCT 0.09
- CRBP 1.06
- MACD
- FCT -0.00
- CRBP 1.12
- Stochastic Oscillator
- FCT 55.52
- CRBP 56.20
About FCT First Trust Senior Floating Rate Income Fund II of Beneficial Interest
First Trust Senior Floating Rate Income Fund II is the United States based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, the fund attempts to preserve capital. The fund seeks to achieve the objectives by investing in a portfolio of senior floating-rate loan interests. Its portfolio of investments consists of aerospace and defense, agricultural products, broadcasting, cable and satellite, electric utilities and other sectors.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.